Immunotherapy in Myeloma
Immunotherapy in multiple myeloma, first investigated with allogeneic stem cell transplantation, is now a major pillar in the treatment of multiple myeloma. CAR-T-cell technology, monoclonal or bispecific antibodies, as well as new forms of cellular therapy, have revolutionized the treatment of this...
Guardat en:
| Format: | Online |
|---|---|
| Idioma: | anglès |
| Publicat: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Matèries: | |
| Accés en línia: | ONIX_20220224_9783036529073_75 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
| _version_ | 1869517034947084288 |
|---|---|
| collection | Directory of Open Access Books |
| description | Immunotherapy in multiple myeloma, first investigated with allogeneic stem cell transplantation, is now a major pillar in the treatment of multiple myeloma. CAR-T-cell technology, monoclonal or bispecific antibodies, as well as new forms of cellular therapy, have revolutionized the treatment of this hematological malignancy. |
| format | Online |
| id | doab-20.500.12854ir-78777 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-787772024-03-30T23:22:00Z Immunotherapy in Myeloma Kröger, Nicolaus Garderet, Laurent multiple myeloma immunotherapy daratumumab BCMA bi-specific T cell engagers chimeric antigen receptor relapse cytokine-release syndrome allogeneic transplantation myeloablative non-myeloablative new drugs CAR T antibodies monoclonal bispecific immunoconjugates antibody-drug conjugates myeloma NK cells immunomodulation cell therapy graft-versus-myeloma donor lymphocyte infusion allogeneic stem cell transplantation prophylaxis salvage CAR T-cells target antigen n/a thema EDItEUR::M Medicine and Nursing Immunotherapy in multiple myeloma, first investigated with allogeneic stem cell transplantation, is now a major pillar in the treatment of multiple myeloma. CAR-T-cell technology, monoclonal or bispecific antibodies, as well as new forms of cellular therapy, have revolutionized the treatment of this hematological malignancy. 2022-02-24T10:36:07Z 2022-02-24T10:36:07Z 2022 book ONIX_20220224_9783036529073_75 9783036529073 9783036529066 https://directory.doabooks.org/handle/20.500.12854/78777 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/4871 https://mdpi.com/books/pdfview/book/4871 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-2907-3 10.3390/books978-3-0365-2907-3 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036529073 9783036529066 124 Basel open access |
| spellingShingle | multiple myeloma immunotherapy daratumumab BCMA bi-specific T cell engagers chimeric antigen receptor relapse cytokine-release syndrome allogeneic transplantation myeloablative non-myeloablative new drugs CAR T antibodies monoclonal bispecific immunoconjugates antibody-drug conjugates myeloma NK cells immunomodulation cell therapy graft-versus-myeloma donor lymphocyte infusion allogeneic stem cell transplantation prophylaxis salvage CAR T-cells target antigen n/a thema EDItEUR::M Medicine and Nursing Immunotherapy in Myeloma |
| title | Immunotherapy in Myeloma |
| title_full | Immunotherapy in Myeloma |
| title_fullStr | Immunotherapy in Myeloma |
| title_full_unstemmed | Immunotherapy in Myeloma |
| title_short | Immunotherapy in Myeloma |
| title_sort | immunotherapy in myeloma |
| topic | multiple myeloma immunotherapy daratumumab BCMA bi-specific T cell engagers chimeric antigen receptor relapse cytokine-release syndrome allogeneic transplantation myeloablative non-myeloablative new drugs CAR T antibodies monoclonal bispecific immunoconjugates antibody-drug conjugates myeloma NK cells immunomodulation cell therapy graft-versus-myeloma donor lymphocyte infusion allogeneic stem cell transplantation prophylaxis salvage CAR T-cells target antigen n/a thema EDItEUR::M Medicine and Nursing |
| topic_facet | multiple myeloma immunotherapy daratumumab BCMA bi-specific T cell engagers chimeric antigen receptor relapse cytokine-release syndrome allogeneic transplantation myeloablative non-myeloablative new drugs CAR T antibodies monoclonal bispecific immunoconjugates antibody-drug conjugates myeloma NK cells immunomodulation cell therapy graft-versus-myeloma donor lymphocyte infusion allogeneic stem cell transplantation prophylaxis salvage CAR T-cells target antigen n/a thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20220224_9783036529073_75 |